Cite
Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions.
MLA
Chu, Jessica, et al. “Evaluation of Encequidar as An Intestinal P-Gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-Gp and BCRP in Drug-Drug Interactions.” Pharmaceutical Research, vol. 40, no. 11, Nov. 2023, pp. 2567–84. EBSCOhost, https://doi.org/10.1007/s11095-023-03563-4.
APA
Chu, J., Panfen, E., Wang, L., Marino, A., Chen, X.-Q., Fancher, R. M., Landage, R., Patil, O., Desai, S. D., Shah, D., Xue, Y., Sinz, M., & Shen, H. (2023). Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions. Pharmaceutical Research, 40(11), 2567–2584. https://doi.org/10.1007/s11095-023-03563-4
Chicago
Chu, Jessica, Erika Panfen, Linna Wang, Anthony Marino, Xue-Qing Chen, R. Marcus Fancher, Raviraj Landage, et al. 2023. “Evaluation of Encequidar as An Intestinal P-Gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-Gp and BCRP in Drug-Drug Interactions.” Pharmaceutical Research 40 (11): 2567–84. doi:10.1007/s11095-023-03563-4.